Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
0.930
-0.130 (-12.25%)
At close: Apr 28, 2026, 4:00 PM EDT
0.916
-0.014 (-1.52%)
After-hours: Apr 28, 2026, 7:58 PM EDT
Skye Bioscience Employees
Skye Bioscience had 12 employees as of December 31, 2025. The number of employees decreased by 4 or -25.00% compared to the previous year.
Employees
12
Change (1Y)
-4
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$4,660,401
Market Cap
32.67M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Aligos Therapeutics | 82 |
| Evaxion | 46 |
| NextCure | 40 |
| Palatin Technologies | 29 |
| Boundless Bio | 28 |
| INmune Bio | 21 |
| Veru Inc. | 20 |
SKYE News
- 21 days ago - Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit - GlobeNewsWire
- 26 days ago - Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development - GlobeNewsWire
- 7 weeks ago - Skye Bioscience Earnings Call Transcript: Q4 2025 - Transcripts
- 7 weeks ago - Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 - GlobeNewsWire
- 3 months ago - Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year - Benzinga
- 3 months ago - Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide - GlobeNewsWire
- 3 months ago - Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference - GlobeNewsWire